ArticlePloS one2016
Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Meprin β regulates osteopontin-signaling in ischemia/reperfusion-induced kidney injury.BMC nephrology · 2025Article
- Urinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis.Diagnostics (Basel, Switzerland) · 2024Article
- The Association of Anti-Sm with Osteopontin Related to Cognitive Impairment in a Pristane-Induced Lupus BALB/c Mice Model.International journal of molecular sciences · 2024Article
- Circulating B Lymphocyte Subsets in Patients with Systemic Lupus Erythematosus.Medicina (Kaunas, Lithuania) · 2024Article
- Angiogenesis in the Outer Membrane of Chronic Subdural Hematomas through Thrombin-Cleaved Osteopontin and the Integrin α9 and Integrin β1 Signaling Pathways.Biomedicines · 2023Article
- Osteopontin as a Biomarker in Chronic Kidney Disease.Biomedicines · 2023Review
- Associations of serum keratin 1 with thyroid function and immunity in Graves' disease.PloS one · 2023Article
- Osteopontin in autoimmune disorders: current knowledge and future perspective.Inflammopharmacology · 2022Review
- Osteopontin-A Potential Biomarker for IgA Nephropathy: Machine Learning Application.Biomedicines · 2022Article
- Review
- Both Full-Length and Protease-Cleaved Products of Osteopontin Are Elevated in Infectious Diseases.Biomedicines · 2021Review
- Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome.Frontiers in immunology · 2021Article
- Plasma Osteopontin Levels is Associated with Biochemical Markers of Kidney Injury in Patients with Leptospirosis.Diagnostics (Basel, Switzerland) · 2020Article
- The Impact of Glycosylation of Osteopontin on Urinary Stone Formation.International journal of molecular sciences · 2019Article
- Osteopontin Gene Polymorphism and Urinary OPN Excretion in Patients with Immunoglobulin A Nephropathy.Cells · 2019Article
- The role of osteopontin in kidney diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Review
- Precision medicine in lupus nephritis: can biomarkers get us there?Translational research : the journal of laboratory and clinical medicine · 2018Review
- Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases?International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed the utility of two forms of osteopontin (OPN), OPN full and its cleaved form (OPN N-half), in plasma and urine as markers of disease activity in lupus nephritis (LN). Samples were collected from patients with systemic lupus erythematosus (SLE) (LN: N = 29, non-LN: N = 27), IgA nephropathy (IgAN) (N = 14), minimal change nephrotic syndrome (MCNS) (N = 5), diabetic nephropathy (DN) (N = 14) and healthy volunteers (HC) (N = 17). While there was no significant difference in urine OPN full concentration between groups, urine OPN N-half concentration was significantly higher in patients with LN than HC (p < 0.05). Moreover, urine OPN N-half was higher in LN patients with overt proteinuria (urine protein/creatinine ratio: P/C > 0.5) than LN patients with minimal proteinuria (P/C < 0.5, p < 0.0001), and also higher than in DN patients with overt proteinuria (P/C > 0.5, p < 0.01). Urine thrombin activity correlated with urine OPN N-half concentration (p < 0.0001), but not with urine OPN full concentration. These results suggest that urine OPN N-half concentration reflects renal inflammation. Thus, urine OPN N-half may be a novel disease activity marker for LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.